3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
147
Cholangiocarcinoma
26
Liver Neoplasms
17
Stomach Neoplasms
13
Biliary Tract Neoplasms
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Neoplasms
7
Esophageal Squamous Cell Carcinoma
5
Colorectal Neoplasms
5
Recurrence
4
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Liver Diseases
3
Esophageal Neoplasms
3
Cirrhosis, Familial, with Pulmonary Hypertension
3
Carcinoma
3
Advanced Biliary Tract Cancer
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms, Glandular and Epithelial
2
Melanoma
2
Hepatitis B
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Biliary Tract Neoplasms Immunotherapy
2
Uterine Cervical Neoplasms
1
Interventions
pembrolizumab
23
Gemcitabine
9
Nivolumab
7
Carboplatin
7
Trastuzumab
6
Early Intervention, Educational
6
avelumab
5
atezolizumab
5
Docetaxel
5
Cisplatin
5
cemiplimab
4
Standard of Care
4
Psychiatric Rehabilitation
4
Paclitaxel
4
Methods
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Fluorouracil
4
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Counseling
4
Albumin-Bound Paclitaxel
4
tisotumab vedotin
3
pertuzumab
3
fludarabine
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
lenvatinib
×
Gastrointestinal
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled